New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

FDA committee recommends Sandoz biosimilar for approval

If approved by the agency, Sandoz will market the biosimilar under the name ZARXIO.

The U.S. is inching closer to approving its first biosimilar.

The FDA's Oncologic Drugs Advisory Committee unanimously recommended the approval of Sandoz' biosimilar that is comparable to Amgen's Neupogen.

"We are pleased with the ODAC's recommendation to approve our biosimilar filgrastim and we look forward to continuing to work with FDA as it completes its review of our filing," said Mark McCamish, M.D., Ph.D., Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz, in a news release.

The decision came after recent documents from FDA reviewers decided that there are "no clinically meaningful difference" between Amgen's Neupogen, and Sandoz's biosimilar version.

If approved in the U.S., Sandoz proposes to market the biosimilar under the name ZARXIO.

The drug is used during chemotherapy to fight off infections.

Sandoz is a Novartis company. 

Discover the right packaging solutions for life sciences in Philadelphia
Explore innovative packaging and supply chain solutions for the life sciences at the largest PACK EXPO East in history, March 18–20. Get ideas from 400+ top exhibitors and connect with colleagues and industry experts—all in one convenient location!
Read More
Discover the right packaging solutions for life sciences in Philadelphia
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts